Drug intelligence / Profile preview

MK-6552

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-6552 is an orally bioavailable small molecule drug developed by Merck Sharp & Dohme for the treatment of narcolepsy, specifically narcolepsy type 1. Its precise mechanism of action has not been disclosed or remains undefined. Clinical development reached Phase 1, with studies evaluating its safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) in both healthy volunteers and patients with narcolepsy. As of late 2024, clinical trials in the United States were terminated due to business reasons rather than safety or efficacy concerns[1][2][5][7][8].

Beyond the preview

Go deeper on MK-6552.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-6552.

Explore the full profile